Deucravacitinib for Psoriasis
(ARTISTYK Trial)

Recruiting in Palo Alto (17 mi)

+74 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Bristol-Myers Squibb

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.

Eligibility Criteria

This trial is for men and women who have had stable plaque psoriasis for at least 6 months, with moderate-to-severe symptoms. Participants should have a noticeable impact on their quality of life due to psoriasis and be suitable candidates for phototherapy or systemic therapy, with at least 3% body surface area affected.

Inclusion Criteria

My doctor thinks I should get light or drug treatment.

I have had stable plaque psoriasis for over 6 months without major changes.

I have moderate-to-severe plaque psoriasis.

+2 more

Exclusion Criteria

Other protocol-defined inclusion/exclusion criteria apply.

My psoriasis is not plaque type but another form like guttate or pustular.

Participant Groups

The study is testing the effects of Deucravacitinib on improving the quality of life in people with plaque psoriasis compared to a placebo. It's set in a real-world community setting rather than a hospital.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DeucravacitinibExperimental Treatment1 Intervention

Group II: Placebo then DeucravacitinibPlacebo Group2 Interventions

Deucravacitinib is already approved in United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Sotyktu for: